Evidence map›Paper›PMID 32265985›Full record

ArticleFrontiers in genetics2020

Evaluation of the Prognostic Value of STEAP1 in Lung Adenocarcinoma and Insights Into Its Potential Molecular Pathways via Bioinformatic Analysis.

Qiang Guo, Xi-Xian Ke, Zhou Liu, Wei-Long Gao, Shi-Xu Fang, Cheng Chen, Yong-Xiang Song, Hao Han, Hong-Ling Lu, Gang Xu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Targeting STEAP1 as an anticancer strategy.Frontiers in oncology · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Qiang GuoDepartment of Thoracic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Xi-Xian KeDepartment of Thoracic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Zhou LiuDepartment of Cardiac Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Wei-Long GaoDepartment of Cardiac Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Shi-Xu FangDepartment of Thoracic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Cheng ChenDepartment of Thoracic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Yong-Xiang SongDepartment of Thoracic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Hao HanDepartment of Thoracic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Hong-Ling LuDepartment of Biochemistry, Zunyi Medical University, Zunyi, China.
Gang XuDepartment of Thoracic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Zunyi Medical University · CNAffiliated Hospital of Guizhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUpregulation of the six-transmembrane epithelial antigen of prostate-1 (STEAP1) is closely associated with prognosis of numerous malignant cancers. However, its role in lung adenocarcinoma (LUAD), the most common type of lung cancer, remains unknown. This study aimed to investigate the role of STEAP1 in the occurrence and progression of LUAD and the potential mechanisms underlying its regulatory effects.

methodsSTEAP1 mRNA and protein expression were analyzed in 40 LUAD patients via real-time PCR and western blotting, respectively. We accessed the clinical data of 522 LUAD patients from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) to investigate the expression and prognostic role of STEAP1 in LUAD. Further, we performed gene ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, and gene set enrichment analysis (GSEA) to elucidate the potential mechanism underlying the role of STEAP1 in LUAD. The protein-protein interaction (PPI) network of STEAP1 was analyzed using the Search Tool for the Retrieval of Interacting Genes (STRING) database, and hub genes with significant positive and negative associations with STEAP1 were identified and their role in LUAD prognosis was predicted.

resultsSTEAP1 was significantly upregulated in LUAD patients and associated with LUAD prognosis. Further, TCGA data indicated that STEAP1 upregulation is correlated with the clinical prognosis of LUAD. GO and KEGG analysis revealed that the genes co-expressed with STEAP1 were primarily involved in cell division, DNA replication, cell cycle, apoptosis, cytokine signaling, NF-kB signaling, and TNF signaling. GSEA revealed that homologous recombination, p53 signaling pathway, cell cycle, DNA replication, apoptosis, and toll-like receptor signaling were highly enriched upon STEAP1 upregulation. Gene Expression Profiling Interactive Analysis (GEPIA) analysis revealed that the top 10 hub genes associated with STEAP1 expression were also associated with the LUAD prognosis.

conclusionSTEAP1 upregulation potentially influences the occurrence and progression of LUAD and its co-expressed genes via regulation of homologous recombination, p53 signaling, cell cycle, DNA replication, and apoptosis. STEAP1 is a potential prognostic biomarker for LUAD.

Indexed as

gene set enrichment analysisKyoto Encyclopedia of Genes and GenomesLUADSTEAP1The Cancer Genome Atlas

Identifiers

PMID32265985
PMCPMC7099762
OpenAlexW3011440530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.